|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor staging, either postoperatively or by imaging, and measuring the tumor markers thyroglobulin for DTC and calcitonin for MTC, allow for dynamic risk-adapted stratification for follow-up procedures.
|
27742787 |
2016 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Routine thyroglobulin, neck ultrasound and physical examination in the routine follow up of patients with differentiated thyroid cancer-Where is the evidence?
|
30128957 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report an innovative fiber optic nano-optrode based on Long Period Gratings (LPGs) working in reflection mode for the detection of human Thyroglobulin (TG), a protein marker of differentiated thyroid cancer.
|
26896794 |
2016 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, TgAb in different concentrations had an effect on the diagnosis of metastasis of differentiated thyroid cancer via Tg.
|
29442477 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and <sup>131</sup>I Ablation.
|
29665748 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of our study was to verify the diagnostic accuracy of <sup>131</sup>I-pT-WBS and SPECT/CT imaging (post-therapeutic imaging) compared to serum Tg levels in detecting metastases in early stage of DTC patients.
|
29707123 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome.
|
28467308 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
A highly sensitive thyroglobulin assay (Elecsys® Tg II, Roche Diagnostics, Penzberg, Germany) has become available for monitoring patients with differentiated thyroid cancer (DTC).
|
28960391 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum thyroglobulin monitoring along with anatomic and functional imaging play key roles in the surveillance of patients with differentiated thyroid cancer after initial treatment.
|
30717906 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend.
|
30963467 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to assess the association between ablative stimulated Tg obtained before radioactive iodine ablation therapy (RAI) (ASTg) and late stimulated Tg obtained 6-12 months after primary therapy (LSTg) in a group of subjects with DTC.
|
28258491 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These techniques were used to model the relationship between thyroglobulin levels in individuals with differentiated thyroid cancer before and after treatment with radioactive iodine (I-131).
|
29557257 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessing the utility of preoperative serum thyroglobulin in differentiated thyroid cancer: a retrospective cohort study.
|
29948933 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without <sup>131</sup>I Ablation.
|
29860933 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prognostic Value of Stimulated Thyroglobulin Levels at the Time of Radioiodine Administration in Differentiated Thyroid Cancer.
|
30283740 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that rosiglitazone treatment may induce radioiodine uptake in some patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
|
17188145 |
2006 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
|
27655291 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients.
|
14715824 |
2004 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the measurement of thyroglobulin mRNA from peripheral blood is likely to affect the future management of these patients, it is expected that serum thyroglobulin measurement will continue to have a principal role in the care of patients with differentiated thyroid cancer.
|
11444170 |
2001 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A higher elevation of Tg levels after RAI may be associated with a better treatment outcome in DTC patients with distant metastasis.
|
30382500 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fourteen patients with DTC (21%) had Tg antibodies, three with local disease (all positive for TSHR-mRNA), and 11 with no evidence of disease (all negative for TSHR-mRNA).
|
15292293 |
2004 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study population (Group A) included all patients with low-risk differentiated thyroid cancer (DTC) who underwent total thyroidectomy and RAI between 1/1/2006 to 9/11/2015 with intrathyroidal T1-T2, Nx, N0 or N1a (≤5 nodes all measuring, when reported, <2 mm) that had anti-thyroglobulin antibodies.
|
28510122 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is an institutional review board-approved retrospective study of patients who underwent lymph node fine needle aspiration biopsy with thyroglobulin washout between 2012 and 2018, during the post-total thyroidectomy follow-up of differentiated thyroid cancer.
|
31495510 |
2020 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of the ability of stimulated thyroglobulin (Tg) and Tg reduction index (TRI) to predict long-term remission in patients with DTC managed by thyroidectomy and radioactive iodine (RAI) remnant ablation.
|
30785995 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> In patients with differentiated thyroid cancer (DTC) and raising serum thyroglobulin (Tg) after total or near-total thyroidectomy and <sup>131</sup>I remnant ablation an empiric <sup>131</sup>I therapy may be considered.
|
30930852 |
2019 |